GlaxoSmithKline PLC
F:GS7
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
GlaxoSmithKline PLC
F:GS7
|
UK |
|
B
|
BankUnited Inc
XBER:BNU
|
US |
|
S
|
Smith & Wesson Brands Inc
F:SWS
|
US |
|
X
|
Xylem Inc
SWB:XY6
|
US |
|
M
|
McEwen Mining Inc
TSX:MUX
|
CA |
|
W
|
WEG SA
OTC:WEGZY
|
BR |
|
M
|
MKS Instruments Inc
F:MKT
|
US |
|
T
|
Teekay Tankers Ltd
NYSE:TNK
|
CA |
|
P
|
PC Connection Inc
XMUN:PCC
|
US |
|
S
|
Stroeer SE & Co KgaA
DUS:SAX
|
DE |
|
SiTime Corp
NASDAQ:SITM
|
US |
|
I
|
Innate Pharma SA
OTC:IPHYF
|
FR |
|
Smith & Wesson Brands Inc
NASDAQ:SWBI
|
US |
|
ACS Actividades de Construccion y Servicios SA
LSE:0HAC
|
ES |
GlaxoSmithKline PLC
GlaxoSmithKline, or GSK, is a global drug maker focused on prescription medicines and vaccines. It develops and sells treatments for areas such as respiratory disease, HIV, immunology, oncology, and infectious disease, along with vaccines for children, adults, and travel-related prevention. Its main customers are governments, health systems, hospitals, doctors, and pharmacies that buy and distribute its products to patients. GSK makes money mainly by selling branded medicines and vaccines, with some added income from licensing and collaboration deals. Unlike a generic drug maker, it depends on research, clinical testing, regulatory approval, and long product lifecycles to protect its drugs and vaccines. That means the business is tied closely to intellectual property and the success of a relatively small number of major products. What makes GSK stand out is its strong position in vaccines and in specialty medicines for large chronic and infectious diseases. It is not a broad consumer health company anymore; after separating that business, GSK became a more focused biopharma company. For investors, it is best understood as a research-driven healthcare supplier that sells patented medicines and vaccines to the medical system.
GlaxoSmithKline, or GSK, is a global drug maker focused on prescription medicines and vaccines. It develops and sells treatments for areas such as respiratory disease, HIV, immunology, oncology, and infectious disease, along with vaccines for children, adults, and travel-related prevention. Its main customers are governments, health systems, hospitals, doctors, and pharmacies that buy and distribute its products to patients.
GSK makes money mainly by selling branded medicines and vaccines, with some added income from licensing and collaboration deals. Unlike a generic drug maker, it depends on research, clinical testing, regulatory approval, and long product lifecycles to protect its drugs and vaccines. That means the business is tied closely to intellectual property and the success of a relatively small number of major products.
What makes GSK stand out is its strong position in vaccines and in specialty medicines for large chronic and infectious diseases. It is not a broad consumer health company anymore; after separating that business, GSK became a more focused biopharma company. For investors, it is best understood as a research-driven healthcare supplier that sells patented medicines and vaccines to the medical system.
Strong quarter: GSK said Q1 sales rose 5% to more than GBP 7.6 billion, with core operating profit up 10% and EPS up 9%.
Growth drivers: Specialty Medicines grew 14%, led by Shingrix, Nucala, Jemperli and HIV medicines, while General Medicines fell 6%.
Pipeline push: Management emphasized faster late-stage development, with multiple Phase III starts in 2025 and more coming this year, plus a more aggressive approach to business development.
HIV momentum: HIV sales grew 10%, and the company reiterated its plan to launch twice-yearly and three-times-yearly long-acting options later this decade.
Bepi progress: Bepirovirsen showed positive Phase III headline data, and GSK said regulatory reviews are moving ahead in the U.S. and China ahead of the October PDUFA date.
Full-year view: The company confirmed its February guidance and said profit growth should be weighted to the second half of the year.
Management
Emma Natasha Walmsley is a prominent British business executive known for her role as the CEO of GlaxoSmithKline (GSK), one of the world's leading pharmaceutical companies. Born on June 6, 1969, in Barrow-in-Furness, England, she pursued her education at Oxford University, where she earned a degree in Classics and Modern Languages. Before joining GSK, Walmsley had an extensive career at L'Oréal, where she spent 17 years in various leadership roles, particularly focusing on marketing and management across different global markets. This experience in consumer goods provided her with a strong foundation in business leadership and global operations. In 2010, Walmsley joined GSK's Consumer Healthcare division. Her strategic insights and leadership skills quickly gained recognition, leading her to become the president of Consumer Healthcare Europe in just a few years. In 2015, she was appointed as the CEO of GSK's Consumer Healthcare business, a joint venture with Novartis at the time, further solidifying her reputation within the pharmaceutical industry. In April 2017, Emma Walmsley broke new ground by becoming the first female CEO of GSK, succeeding Sir Andrew Witty. Her appointment marked her as one of the few women leading major pharmaceutical companies worldwide. As CEO, Walmsley has focused on streamlining GSK's operations, emphasizing innovation in pharmaceuticals and vaccines, and steering the strategic spin-off of the company's consumer healthcare division. Under her leadership, GSK has pursued significant advancements in areas such as oncology, immunology, and infectious diseases, reflecting her commitment to strengthening the company's research and development capabilities. Emma Walmsley's tenure at GSK is noted for her efforts to create a more agile, science-driven organization and for advocating gender diversity and leadership opportunities for women within the business.
Before joining GSK, Walmsley had an extensive career at L'Oréal, where she spent 17 years in various leadership roles, particularly focusing on marketing and management across different global markets. This experience in consumer goods provided her with a strong foundation in business leadership and global operations.
In 2010, Walmsley joined GSK's Consumer Healthcare division. Her strategic insights and leadership skills quickly gained recognition, leading her to become the president of Consumer Healthcare Europe in just a few years. In 2015, she was appointed as the CEO of GSK's Consumer Healthcare business, a joint venture with Novartis at the time, further solidifying her reputation within the pharmaceutical industry.
In April 2017, Emma Walmsley broke new ground by becoming the first female CEO of GSK, succeeding Sir Andrew Witty. Her appointment marked her as one of the few women leading major pharmaceutical companies worldwide. As CEO, Walmsley has focused on streamlining GSK's operations, emphasizing innovation in pharmaceuticals and vaccines, and steering the strategic spin-off of the company's consumer healthcare division.
Under her leadership, GSK has pursued significant advancements in areas such as oncology, immunology, and infectious diseases, reflecting her commitment to strengthening the company's research and development capabilities. Emma Walmsley's tenure at GSK is noted for her efforts to create a more agile, science-driven organization and for advocating gender diversity and leadership opportunities for women within the business.
Julie Belita Brown A.C.A. is a distinguished business executive known for her impactful career in the pharmaceutical industry, primarily associated with GlaxoSmithKline PLC (GSK). She holds the designation of Associate of the Institute of Chartered Accountants (A.C.A.), which highlights her strong background in finance and accounting. Julie Brown served as the Chief Financial Officer (CFO) of GSK and played a significant role in the company’s financial operations and strategic planning. Her leadership at GSK was marked by a commitment to financial stewardship, efficiency, and supporting the company's broader mission to improve global health. With a deep understanding of the pharmaceutical sector, her expertise was instrumental in navigating complex financial landscapes and contributing to the company's growth and innovation objectives. Prior to her tenure at GSK, Julie Brown held various senior positions in other prominent organizations, bringing a wealth of experience to her role at GSK. Her career is characterized by a focus on financial excellence, strategic decision-making, and a dedication to fostering a collaborative and inclusive workplace culture. Julie Brown is widely respected for her professional acumen and her contributions to the industry, and her work continues to influence the global pharmaceutical field.
Julie Brown served as the Chief Financial Officer (CFO) of GSK and played a significant role in the company’s financial operations and strategic planning. Her leadership at GSK was marked by a commitment to financial stewardship, efficiency, and supporting the company's broader mission to improve global health. With a deep understanding of the pharmaceutical sector, her expertise was instrumental in navigating complex financial landscapes and contributing to the company's growth and innovation objectives.
Prior to her tenure at GSK, Julie Brown held various senior positions in other prominent organizations, bringing a wealth of experience to her role at GSK. Her career is characterized by a focus on financial excellence, strategic decision-making, and a dedication to fostering a collaborative and inclusive workplace culture.
Julie Brown is widely respected for her professional acumen and her contributions to the industry, and her work continues to influence the global pharmaceutical field.
Shobie Ramakrishnan is a prominent figure in the pharmaceutical industry, currently serving as the Chief Digital and Technology Officer at GlaxoSmithKline plc (GSK). In her role, she is responsible for leading GSK's digital transformation and technology strategy, aiming to leverage digital tools and innovation to enhance the company's operations and deliver better health outcomes. Ramakrishnan joined GSK with extensive experience in driving digital initiatives and transformative technology solutions across various sectors. Before her tenure at GSK, she held significant roles in global companies where she focused on implementing technology-driven strategies. Her leadership is instrumental in fostering a culture of innovation within GSK, focusing on utilizing data and digital platforms to support pharmaceutical development and healthcare delivery. With a strong background in technology and business strategy, Shobie Ramakrishnan is committed to advancing GSK's mission through digital excellence, ensuring the company remains at the forefront of scientific and technological advancements in the healthcare industry.
Ramakrishnan joined GSK with extensive experience in driving digital initiatives and transformative technology solutions across various sectors. Before her tenure at GSK, she held significant roles in global companies where she focused on implementing technology-driven strategies. Her leadership is instrumental in fostering a culture of innovation within GSK, focusing on utilizing data and digital platforms to support pharmaceutical development and healthcare delivery.
With a strong background in technology and business strategy, Shobie Ramakrishnan is committed to advancing GSK's mission through digital excellence, ensuring the company remains at the forefront of scientific and technological advancements in the healthcare industry.
Tony Wood is a notable figure in the pharmaceutical industry, currently serving as the Chief Scientific Officer at GlaxoSmithKline PLC (GSK). With a career spanning over three decades, Tony Wood has played a crucial role in the field of drug discovery and development. Before joining GSK, Tony Wood built a distinguished career at Pfizer, where he made significant contributions in various leadership roles, ultimately serving as the Senior Vice President and Head of Worldwide Medicinal Chemistry. During his tenure at Pfizer, he was instrumental in pioneering advancements in medicinal chemistry and drug design. In his role at GSK, Tony Wood leads the company's Research & Development (R&D) efforts, focusing on innovative approaches to drug discovery that leverage cutting-edge science and technology. His leadership is central to GSK's strategic focus on harnessing the power of genetics and genomics in the development of new therapies. Tony Wood is recognized for his forward-thinking vision in integrating scientific disciplines to accelerate the delivery of novel medicines. His commitment to scientific excellence and collaboration has been a driving force in advancing GSK's mission to improve patient outcomes and address unmet medical needs.
Before joining GSK, Tony Wood built a distinguished career at Pfizer, where he made significant contributions in various leadership roles, ultimately serving as the Senior Vice President and Head of Worldwide Medicinal Chemistry. During his tenure at Pfizer, he was instrumental in pioneering advancements in medicinal chemistry and drug design.
In his role at GSK, Tony Wood leads the company's Research & Development (R&D) efforts, focusing on innovative approaches to drug discovery that leverage cutting-edge science and technology. His leadership is central to GSK's strategic focus on harnessing the power of genetics and genomics in the development of new therapies.
Tony Wood is recognized for his forward-thinking vision in integrating scientific disciplines to accelerate the delivery of novel medicines. His commitment to scientific excellence and collaboration has been a driving force in advancing GSK's mission to improve patient outcomes and address unmet medical needs.
As of the latest available information, Sarah Elton-Farr is the Head of Corporate Communications at GlaxoSmithKline PLC (GSK), a leading global healthcare company. In her role, she is responsible for overseeing the company's external and internal communications strategies, ensuring clear and effective communication of GSK's objectives, initiatives, and corporate values to various stakeholders, including employees, investors, media, and the public. Elton-Farr has a background in corporate communications and has held various roles across industries that enhance her expertise in managing corporate reputation and strategic communications. Her leadership at GSK contributes to the company's mission of improving global health through innovative solutions and fostering transparent, quality communications.
David Simon Redfern is a prominent executive at GlaxoSmithKline PLC (GSK), a global healthcare company. Holding the degree of BSc (Hons) and recognized as a Chartered Accountant (CA), Redfern has held several significant roles within the organization. He joined GSK in 1994 and has since accumulated extensive experience across various functions in the company. Over the years, Redfern has been involved in numerous strategic initiatives and leadership roles that contributed to the company's growth and innovation in the pharmaceutical sector. His work often includes a focus on corporate strategy, business development, and operational excellence, reflecting his expertise in navigating complex healthcare markets. His career highlights also encompass driving organizational change and transformation to ensure that GSK remains at the forefront of drug development and healthcare delivery. Redfern's contributions have been instrumental in shaping the company's strategic direction and improving its competitive position in the industry. In addition to his technical and strategic acumen, Redfern is recognized for his leadership skills and commitment to fostering a dynamic work environment that supports innovation and efficiency within GSK.
Over the years, Redfern has been involved in numerous strategic initiatives and leadership roles that contributed to the company's growth and innovation in the pharmaceutical sector. His work often includes a focus on corporate strategy, business development, and operational excellence, reflecting his expertise in navigating complex healthcare markets.
His career highlights also encompass driving organizational change and transformation to ensure that GSK remains at the forefront of drug development and healthcare delivery. Redfern's contributions have been instrumental in shaping the company's strategic direction and improving its competitive position in the industry.
In addition to his technical and strategic acumen, Redfern is recognized for his leadership skills and commitment to fostering a dynamic work environment that supports innovation and efficiency within GSK.
Diana Conrad is a notable executive at GSK (GlaxoSmithKline PLC). She serves as the Senior Vice President of Human Resources. In her role, she is responsible for overseeing the company's global human resources strategy and operations. Conrad plays a critical role in shaping GSK's workplace culture, leadership development, talent management, and employee engagement initiatives. Her leadership is instrumental in driving the company's efforts to maintain a dynamic and inclusive work environment that supports GSK’s strategic goals in the pharmaceutical and healthcare industry. Her extensive experience in HR helps GSK in attracting, retaining, and developing top talent across its global operations.
Luke V. Miels is a prominent executive in the pharmaceutical industry, serving as the Chief Commercial Officer for GlaxoSmithKline (GSK) PLC. In his role, he is responsible for overseeing GSK's commercial operations, which include global marketing and sales strategies. Miels joined GSK in 2017, bringing a wealth of experience from his previous roles in the pharmaceutical sector. Prior to his tenure at GSK, he held a senior position at AstraZeneca, where he was instrumental in driving the company's growth and performance. Throughout his career, Miels has been highly regarded for his strategic acumen and leadership in transforming commercial practices to enhance competitive performance. His educational background includes a degree in Science and an MBA, which have equipped him with a strong foundation for understanding the complex dynamics of the pharmaceutical industry. Under his leadership, GSK has focused on innovation and commercial excellence, working towards delivering better health outcomes for patients worldwide.
Miels joined GSK in 2017, bringing a wealth of experience from his previous roles in the pharmaceutical sector. Prior to his tenure at GSK, he held a senior position at AstraZeneca, where he was instrumental in driving the company's growth and performance. Throughout his career, Miels has been highly regarded for his strategic acumen and leadership in transforming commercial practices to enhance competitive performance.
His educational background includes a degree in Science and an MBA, which have equipped him with a strong foundation for understanding the complex dynamics of the pharmaceutical industry. Under his leadership, GSK has focused on innovation and commercial excellence, working towards delivering better health outcomes for patients worldwide.
